386 related articles for article (PubMed ID: 30295846)
1. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
3. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
4. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
5. ELISPOT assay of interferon-γ secretion for evaluating human cytomegalovirus reactivation risk in allo-HSCT recipients.
Liang H; Xia J; Zhang R; Yang B; Wu J; Gui G; Huang Y; Chen X; Yang R; Wang H; Gong S; Fan J
J Med Virol; 2021 Nov; 93(11):6301-6308. PubMed ID: 34076905
[TBL] [Abstract][Full Text] [Related]
6. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
7. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
Ariza-Heredia EJ; Winston DJ; Rowley SD; Mullane K; Chandrasekar P; Hari P; Avery RK; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; El Haddad L; Shah DP; Jiang Y; Khawaja F; Dadwal S; Blanchard T; Chemaly RF
Open Forum Infect Dis; 2023 Aug; 10(8):ofad386. PubMed ID: 37636519
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.
Jung J; Lee HJ; Kim SM; Kang YA; Lee YS; Chong YP; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Virol; 2017 Feb; 87():5-11. PubMed ID: 27984766
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
13. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
15. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of cytomegalovirus-specific T-cell response in allogeneic hematopoietic stem cell recipients: the contribution of six frequently recognized, virus-encoded ORFs.
Nemeckova S; Krystofova J; Babiarova K; Hainz P; Musil J; Sroller V; Maly M; Stastna-Markova M
Transpl Infect Dis; 2016 Jun; 18(3):381-9. PubMed ID: 27061389
[TBL] [Abstract][Full Text] [Related]
17. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
19. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
20. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
